OBD and major US Pharma announce agreement to differentiate lymphoma subgroups.

Oxford BioDynamics Limited has entered into a Technology and Evaluation Agreement with a second major US Pharmaceutical Company to identify EpiSwitchTM signatures using their EpiSwitchTM Biomarker discovery platform in order to differentiate Diffuse Large B-cell Lymphoma (DLBCL) prognostic subgroups.

OBD announces signature of a Development Agreement with Janssen Research & Development.

(Oxford, UK and Philadelphia, USA) - Oxford BioDynamics Limited and Janssen Research & Development, LLC. have signed an agreement for the use of the EpiSwitchTM platform technology in the development of epigenetic cancer biomarkers for circulating tumour cells (CTCs).

The development agreement will focus initially on EpiSwitchTM biomarkers signatures for the non-invasive detection of CTCs for high performance diagnostic and prognostic stratifications in patients with prostate cancer. Christian Hoyer Millar, CEO of Oxford BioDynamics said that “Oxford BioDynamics are delighted to have the opportunity of working with Janssen to accelerate the development of a new treatment for prostate cancer”.